PolyPid Ltd. (PYPD)
NASDAQ: PYPD · IEX Real-Time Price · USD
3.430
-0.170 (-4.72%)
At close: Jul 19, 2024, 12:00 AM
3.520
+0.090 (2.62%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
PolyPid Employees
As of December 31, 2023, PolyPid had 62 total employees, including 59 full-time and 3 part-time employees. The number of employees increased by 2 or 3.33% compared to the previous year.
Employees
62
Change (1Y)
2
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$384,919
Market Cap
5.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Biomerica | 62 |
| Ainos | 46 |
| TFF Pharmaceuticals | 19 |
| FSD Pharma | 17 |
| Aethlon Medical | 14 |
| Sonoma Pharmaceuticals | 10 |
| TransCode Therapeutics | 10 |
| Oragenics | 5 |
PYPD News
- 6 weeks ago - PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial - GlobeNewsWire
- 2 months ago - PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - PolyPid to Participate in Citizens JMP Life Sciences Conference - GlobeNewsWire
- 2 months ago - PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - GlobeNewsWire
- 3 months ago - PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024 - GlobeNewsWire
- 5 months ago - PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference - GlobeNewsWire
- 5 months ago - PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 5 months ago - PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial - GlobeNewsWire